Andrew Saik - Jan 27, 2023 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Role
EVP & Chief Financial Officer
Signature
/s/ Rocco Venezia, as attorney-in-fact
Stock symbol
ICPT
Transactions as of
Jan 27, 2023
Transactions value $
$0
Form type
4
Date filed
1/31/2023, 03:05 PM
Previous filing
Jan 3, 2023
Next filing
Mar 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Award $0 +14.7K +26.11% $0.00 71K Jan 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICPT Option to Purchase Common Stock Award $0 +24K $0.00 24K Jan 27, 2023 Common Stock 24K $18.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.
F2 The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.